Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 12/20 | 0.41 |
| ▸ | TSHR | P16473 | 3/20 | 0.39 |
| ▸ | USP2 | O75604 | 6/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 5/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | PIK3CD | O00329 | 3/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26139846 | 0.79 | CYP2D6 (0.38) | CYP2D6TSHRUSP2CYP1A2HIF1A | |
| SCHEMBL3418584 | 0.75 | PIK3CD (0.51) | CYP2D6TSHRUSP2CYP1A2HIF1A | |
| SCHEMBL27281654 | 0.74 | CYP2D6 (0.47) | CYP2D6TSHRUSP2CYP1A2HIF1A | |
| SCHEMBL24607751 | 0.73 | CYP2D6 (0.42) | CYP2D6TSHRUSP2CYP1A2HIF1A | |
| SCHEMBL25664912 | 0.71 | PIK3CD (0.47) | CYP2D6TSHRUSP2CYP1A2HIF1A | |
| SCHEMBL26139847 | 0.70 | PIK3CD (0.42) | CYP2D6TSHRUSP2CYP1A2HIF1A | |
| SCHEMBL21290764 | 0.70 | CYP2D6 (0.40) | CYP2D6TSHRSMN1; SMN2PIK3CD | |
| SCHEMBL23770532 | 0.70 | CYP2D6 (0.45) | CYP2D6TSHRUSP2CYP1A2HIF1A | |
| SCHEMBL16999001 | 0.70 | CYP2D6 (0.45) | CYP2D6TSHRUSP2CYP1A2HIF1A | |
| SCHEMBL18926690 | 0.69 | CYP2D6 (0.56) | CYP2D6TSHRUSP2CYP1A2HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230212155-A1 | PD-1/PD-L1 INHIBITORS | GILEAD SCIENCES, INC. | 2023-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230212155-A1 | PD-1/PD-L1 INHIBITORS | PDCD1, CD274, PDCD1LG2 | CYP2D6 1710/4885TSHR 2425/4885USP2 3417/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.